| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10969597 | Vaccine | 2012 | 8 Pages |
Abstract
⺠As part of a postmarketing commitment, LAIV safety was studied in approximately 20,000 eligible adults over 5 influenza seasons. ⺠Rate differences of medically attended events suggested no safety signal associated with LAIV. ⺠No serious adverse event occurred at a significantly higher rate after LAIV. ⺠No significant adverse outcomes were identified among eligible adults after LAIV.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Roger Baxter, Seth L. Toback, Frangiscos Sifakis, John Hansen, Joan Bartlett, Laurie Aukes, Ned Lewis, Xionghua Wu, Christopher S. Ambrose,